Biotech companies consider trade secrets as alternative to patents
Biotech IP practitioners at the BIO International Convention warned companies will increasingly look to trade secrets as a result of the courts’ and USPTO’s interpretation of Section 101, while David Kappos, Phil Johnson and Judge Paul Michel gave a gloomy outlook for patent holders
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: